Zentalis holders back directors and auditor
Zentalis Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Zentalis Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026. A total of 49,453,766 shares were present or represented by proxy, representing approximately 69.47% of outstanding common stock as of the April 20, 2026 record date, establishing a strong quorum.
Stockholders elected David Johnson and Jan Skvarka, Ph.D., as Class III directors to serve until the 2029 Annual Meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 and approved, on an advisory basis, the compensation of the named executive officers.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares represented at meeting: 49,453,766 shares
Quorum percentage: 69.47%
Votes for Jan Skvarka, Ph.D.: 23,497,184 votes
+2 more
5 metrics
Shares represented at meeting
49,453,766 shares
Present or by proxy at 2026 Annual Meeting
Quorum percentage
69.47%
Shares outstanding as of April 20, 2026 record date
Votes for Jan Skvarka, Ph.D.
23,497,184 votes
Election as Class III director
Votes for auditor ratification
49,321,951 votes
Ratification of Ernst & Young LLP for 2026 fiscal year
Votes for executive pay
21,949,844 votes
Advisory approval of named executive officer compensation
Key Terms
Annual Meeting of Stockholders, broker non-votes, independent registered public accounting firm, advisory (non-binding) basis, +1 more
5 terms
Annual Meeting of Stockholders financial
"On June 16, 2026, Zentalis Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders"
broker non-votes financial
"NOMINEE | Votes FOR | Votes WITHHELD | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
advisory (non-binding) basis financial
"Approval, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers"
record date financial
"representing approximately 69.47% of the Company’s outstanding common stock as of the April 20, 2026 record date"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was the quorum at Zentalis (ZNTL) 2026 Annual Meeting?
A quorum was reached with 49,453,766 Zentalis shares present or represented by proxy, about 69.47% of outstanding common stock. This level of participation allowed all proposals at the 2026 Annual Meeting to be validly considered and voted upon by stockholders.
Which directors were elected at Zentalis (ZNTL) 2026 Annual Meeting?
Stockholders elected David Johnson and Jan Skvarka, Ph.D., as Class III directors at the 2026 Annual Meeting. They will serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to earlier death, resignation or removal.
Did Zentalis (ZNTL) stockholders ratify the company’s independent auditor for 2026?
Yes. Stockholders ratified Ernst & Young LLP as Zentalis’ independent registered public accounting firm for the fiscal year ending December 31, 2026, with 49,321,951 votes for, 13,557 votes against, 118,258 abstentions, and no broker non-votes recorded on this proposal.
How did Zentalis (ZNTL) stockholders vote on executive compensation in 2026?
On an advisory basis, stockholders approved compensation of Zentalis’ named executive officers, with 21,949,844 votes for, 10,930,673 votes against, 47,136 abstentions, and 16,526,113 broker non-votes. This advisory vote provides stockholder feedback on the company’s executive pay program.
What items were on the agenda at Zentalis (ZNTL) 2026 Annual Meeting?
Stockholders voted on electing two Class III directors, ratifying Ernst & Young LLP as independent registered public accounting firm for the 2026 fiscal year, and approving, on an advisory non-binding basis, the compensation of the company’s named executive officers, all of which received sufficient support.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates